Analyst Rating Update on BioScrip (BIOS)

BioScrip (NASDAQ:BIOS) : 4 analysts are covering BioScrip (NASDAQ:BIOS) and their average rating on the stock is 1.5, which is read as a Strong Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

BioScrip (NASDAQ:BIOS) : The highest level BioScrip (NASDAQ:BIOS) is projected to reach is $5 for the short term and the lowest estimate is at $3. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $3.92 and the possibility the share price can swing is $1.13.

For the current week, the company shares have a recommendation consensus of Buy.

BioScrip (NASDAQ:BIOS): stock turned positive on Tuesday. Though the stock opened at $2.41, the bulls momentum made the stock top out at $2.595 level for the day. The stock recorded a low of $2.41 and closed the trading day at $2.5, in the green by 4.17%. The total traded volume for the day was 982,438. The stock had closed at $2.4 in the previous days trading.

In an insider trading activity, Pate R Carter, director of Bioscrip, Inc., executed a transaction worth $62,500 on June 17, 2016. A total of 25,000 shares were purchased at an average price of $2.5. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

BioScrip, Inc. is engaged in providing infusion and home care management solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payers and pharmaceutical manufacturers to provide patients access to post-acute care services. Its segments include Infusion Services and Pharmacy Benefit Management (PBM) Services. Its Infusion Services segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment, products and services. Its PBM Services segment consists of integrated PBM services, which primarily consists of discount card programs that provide alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. It provides products, services and condition-specific clinical management programs for health conditions, such as gastrointestinal abnormalities, infectious diseases, and others.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.